Home Cart 0 Sign in  

[ CAS No. 911434-04-3 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 911434-04-3
Chemical Structure| 911434-04-3
Structure of 911434-04-3 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 911434-04-3 ]

Related Doc. of [ 911434-04-3 ]

Alternatived Products of [ 911434-04-3 ]

Product Details of [ 911434-04-3 ]

CAS No. :911434-04-3 MDL No. :
Formula : C12H13BrN2O6 Boiling Point : -
Linear Structure Formula :- InChI Key :-
M.W : 361.15 Pubchem ID :-
Synonyms :

Safety of [ 911434-04-3 ]

Signal Word: Class:
Precautionary Statements: UN#:
Hazard Statements: Packing Group:

Application In Synthesis of [ 911434-04-3 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 911434-04-3 ]
  • Downstream synthetic route of [ 911434-04-3 ]

[ 911434-04-3 ] Synthesis Path-Upstream   1~7

  • 1
  • [ 911434-04-3 ]
  • [ 911434-05-4 ]
YieldReaction ConditionsOperation in experiment
96% for 5 h; Heating / reflux 5-Bromo-2-methyl-3-nitro-pyridine
2-(5-Bromo-3-nitro-pyridin-2-yl)-malonic acid diethyl ester (Intermediate 24) (12.6 g) was added to 7.0 N HCl (100 mL) and heated to reflux for 5 hours, the reaction was cooled, extracted with diethyl ether (3*250 mL), dried (MgSO4) and solvent removed in vacuo to yield a yellow oil.
Purification by flash chromatography on silica using 20percent diethylether in iso-hexane as eluent gave the title compound as a yellow waxy solid (7.5 g, 96percent);
1H NMR (300.072 MHz, cdcl3) .box. 8.79 (s, 1H), 8.43 (s, 1H), 2.83 (s, 3H).
95% With hydrogenchloride In waterReflux diethyl (5-bromo-3-nitropyridin-2-yl)propanedioate (6.8 g, 18.8 mmol) was refluxed in 290 ml of 6M HCl overnight. The reaction mixture was allowed to cool down to room temperature, and the mixture was neutralized with NaOH in an ice bath to pH 10. The solution was extracted with dichloromethane (DCM), dried, and evaporated to a yellow solid, 3.88 g, in 95percent yield.
89.7% for 5 h; Reflux Step 2 - Synthesis of 5-bromo-2-methyl-3-nitropyridineA mixture of diethyl 2-(5-bromo-3-nitropyridin-2-yl)malonate (1.2 g, 3.3 mmol) was added to 7.0 N HCl (10 mL) and heated to refluxed for 5 hours, the reaction was cooled to room temperature and extracted with DCM : MeOH = 10 : 1, the organic phase was dried (Na2S04) and concentrated, the resulting residue was purified using column chromatography eluted with PE : EtOAc = 4 : 1 to provide 5-bromo-2-methyl-3-nitropyridine (0.7 g, yield:89.7percent).1H-NMR (CDC13, 400 MHz) δ 8.76 (s, 1H), 8.40 (s, 1H), 2.80 (s, 3H).
89.7% for 5 h; Reflux Step 2 - Synthesis of 5-bromo-2-methyl-3-nitropyridine A mixture of diethyl 2-(5-bromo-3-nitropyridin-2-yl)malonate (1.2 g, 3.3 mmol) was added to 7.0 N HCl (10 mL) and heated to refluxed for 5 hours, the reaction was cooled to room temperature and extracted with DCM : MeOH = 10 : 1, the organic phase was dried (Na2S04) and concentrated, the resulting residue was purified using column chromatography eluted with PE : EtOAc = 4 : 1 to provide 5-bromo-2-methyl-3-nitropyridine (0.7 g, yield:89.7percent). 1H- MR (CDC13, 400 MHz) δ 8.76 (s, 1H), 8.40 (s, 1H), 2.80 (s, 3H). (M+H)+: 217 / 219.
84% With hydrogenchloride In water for 18 h; Reflux Example 635-bromo-2-methyl-3-nitropyridineA stirred mixture of diethyl 2-(5-bromo-3-nitropyridin-2-yl)malonate (12.5 g, 34.6 mmol) in HCI (7 N in water, 200 ml.) is heated at reflux for 18 hours. The mixture is cooled to room temperature and extracted with CH2CI2 (3 x 200 ml_). Organic layer is collected, dried over Na2S04, filtered and concentrated to dryness. The crude product is purified viachromatography using CH2CI2 to afford the title compound (5.8 g, 84percent) as a yellow solid: Rf 0.67 (CH2CI2); LCMS (m/z) = 217.1 , 219.2 [M+H]+, fR = 2.01 min.
83% With hydrogenchloride In water for 3 h; Reflux The title compound is prepared as described in WO 2006/103449 (intermediate 24).C-l (40.0 g, 111 mmol) is taken up in 110 mL IN HC1 and the reaction mixture is stirred under reflux for 3 h. After cooling to RT, the aqueous phase is extracted with DCM, the combined organic layers are washed with saturated aqueous NaHC03-solution, dried over MgS04, filtered, and the solvent is evaporated under reduced pressure. Yield: 20.0 g (83percent).
83% With hydrogenchloride In water for 3 h; Reflux The title compound is prepared as described in WO 2006/103449 (intermediate 24).C-l (40.0 g, 111 mmol) is taken up in 110 mL IN HC1 and the reaction mixture is stirred under reflux for 3 h. After cooling to RT, the reaction mixture is extracted with DCM, the combined organic layers are washed with saturated aqueous NaHC03, dried over MgS04, filtered, and the solvent is removed under reduced pressure. Yield: 20.0 g (83percent).
83% With hydrogenchloride In water for 3 h; Reflux The title compound is prepared as described in (intermediate 24). C-1 (40.0 g, 111 mmol) is taken up in 110 mL 1N HCl and the reaction mixture is stirred under reflux for 3 h. After cooling to RT, the reaction mixture is extracted with DCM, the combined organic layers are washed with saturated aqueous NaHCO3, dried over MgSO4, filtered, and the solvent is removed under reduced pressure. Yield: 20.0 g (83percent).
83% With hydrogenchloride In water for 3 h; Reflux The title compound is prepared as described in WO 2006/103449 (intermediate 24). C-1 (40.0 g, 111 mmol) is taken up in 110 mL 1N HCl and the reaction mixture is stirred under reflux for 3 h.
After cooling to RT, the aqueous phase is extracted with DCM, the combined organic layers are washed with saturated aqueous NaHCO3-solution, dried over MgSO4, filtered, and the solvent is evaporated under reduced pressure. Yield: 20.0 g (83percent).
75% at 105℃; Step 2: 5-Bromo-2-methyl-3-nitropyridine; To diethyl (5-bromo-3-nitropyridin-2-yl)malonate (66 g, 0.18 mol) was added water (250 mL) and 12 M HCl (360 mL, 4.32 mol). The mixture was heated at 105 0C until TLC showed starting material was consumed. The reaction mixture was then allowed to cool to rt and brine (0.67 L) was added. The organic solution was separated and the aqueous solution was extracted with DCM (3 x 0.67L). The organic solutions were combined, washed with brine, sat. aq. NaHCO3, and brine again, dried over Na2SO4, filtered and concentrated to give 5-bromo-2-methyl-3-nitropyridine (34.7 g, 75percent) as a yellow solid.
72%
Stage #1: for 18 h; Reflux
Stage #2: With sodium hydrogencarbonate In water at 0℃;
A mixture of the diethyl 2-(5-bromo-3-nitropyridin-2-yl)malonate (31.8 g, 88 mmol) in aqueous hydrochloric acid (6M, 1.4 L) was stirred at reflux for 18 hours.
The reaction mixture was cooled to ambient temperature and added very slowly to a saturated aqueous solution of aqueous sodium bicarbonate (4 L) at 0° C.
The mixture was then extracted with dichloromethane (7 L), dried over magnesium sulfate and the solvent removed in vacuo to give 5-bromo-2-methyl-3-nitropyridine as an orange oil (13.8 g, 63.9 mmol, 72percent) which solidified upon standing. 1HNMR (300 MHz, CDCl3): δ ppm 8.78 (s, 1H), 8.43 (s, 1H), 2.79 (s, 3H).
72%
Stage #1: for 18 h; Reflux
Stage #2: With sodium hydrogencarbonate In water at 0℃;
A mixture of the diethyl 2-(5-bromo-3-nitropyridin-2-yl)malonate (31 .8 g, 88 mmol) in aqueous hydrochloric acid (6M, 1 .4 L) was stirred at reflux for 18 hours. The reaction mixture was cooled to ambient temperature and added very slowly to a saturated aqueous solution of aqueous sodium bicarbonate (4 L) at 0 °C. The mixture was then extracted with dichloromethane (7 L), dried over magnesium sulfate and the solvent removed in vacuo to give 5-bromo-2-methyl-3-nitropyridine as an orange oil (13.8 g, 63.9 mmol, 72 percent) which solidified upon standing. 1HNMR (300 MHz, CDCI3) : ppm 8.78 (s, 1 H), 8.43 (s, 1 H), 2.79 (s, 3H).
72%
Stage #1: With hydrogenchloride In water for 18 h; Reflux
Stage #2: With sodium hydrogencarbonate In water at 0℃;
A mixture of the diethyl 2-(5-bromo-3-nitropyridin-2-yl)malonate (31.8 g, 88 mmol) in aqueous hydrochloric acid (6 M, 1.4 L) was stirred at reflux for 18 hours. The reaction mixture was cooled to ambient temperature and added very slowly to a saturated aqueous solution of aqueous sodium bicarbonate (4 L) at 0° C. The mixture was then extracted with dichloromethane (7 L), dried over magnesium sulfate and the solvent removed in vacuo to give 5-bromo-2-methyl-3-nitropyridine as an orange oil (13.8 g, 72percent) which solidified upon standing. 1HNMR (300 MHz, CDCl3, δ): 8.78 (s, 1H), 8.43 (s, 1H), 2.79 (s, 3H).

Reference: [1] Patent: US2008/194552, 2008, A1, . Location in patent: Page/Page column 40
[2] Patent: WO2010/68292, 2010, A1, . Location in patent: Page/Page column 78
[3] Patent: WO2013/33899, 2013, A1, . Location in patent: Page/Page column 39
[4] Patent: WO2013/34048, 2013, A1, . Location in patent: Page/Page column 46; 47
[5] Patent: WO2012/88411, 2012, A1, . Location in patent: Page/Page column 64
[6] Patent: WO2012/101184, 2012, A1, . Location in patent: Page/Page column 55
[7] Patent: WO2012/101186, 2012, A1, . Location in patent: Page/Page column 53
[8] Patent: EP2546249, 2013, A1, . Location in patent: Paragraph 0206; 0207
[9] Patent: US2013/23533, 2013, A1, . Location in patent: Paragraph 0230; 0231
[10] Patent: WO2010/65134, 2010, A1, . Location in patent: Page/Page column 89-90
[11] Journal of Medicinal Chemistry, 2012, vol. 55, # 1, p. 197 - 208
[12] Patent: US2011/111046, 2011, A1, . Location in patent: Page/Page column 16
[13] Patent: WO2011/58473, 2011, A1, . Location in patent: Page/Page column 32; 33
[14] Patent: US2012/108619, 2012, A1, . Location in patent: Page/Page column 29
[15] Patent: WO2009/17822, 2009, A2, . Location in patent: Page/Page column 73-74
[16] Journal of Medicinal Chemistry, 2011, vol. 54, # 6, p. 1789 - 1811
[17] Patent: WO2012/87782, 2012, A1, . Location in patent: Page/Page column 74; 75
[18] Patent: WO2016/57834, 2016, A1, . Location in patent: Paragraph 000568
  • 2
  • [ 911434-04-3 ]
  • [ 914358-73-9 ]
Reference: [1] Journal of Medicinal Chemistry, 2011, vol. 54, # 6, p. 1789 - 1811
[2] Patent: US2011/111046, 2011, A1,
[3] Patent: WO2011/58473, 2011, A1,
[4] Patent: WO2012/87782, 2012, A1,
[5] Patent: WO2012/101184, 2012, A1,
[6] Patent: WO2012/101186, 2012, A1,
[7] Patent: EP2546249, 2013, A1,
[8] Patent: US2013/23533, 2013, A1,
[9] Patent: WO2016/57834, 2016, A1,
[10] Patent: US2012/108619, 2012, A1,
  • 3
  • [ 911434-04-3 ]
  • [ 1190319-62-0 ]
Reference: [1] Journal of Medicinal Chemistry, 2012, vol. 55, # 17, p. 7667 - 7685
[2] Patent: WO2016/8593, 2016, A1,
  • 4
  • [ 911434-04-3 ]
  • [ 1150617-54-1 ]
Reference: [1] Patent: US2011/111046, 2011, A1,
[2] Patent: WO2011/58473, 2011, A1,
[3] Patent: WO2012/87782, 2012, A1,
[4] Patent: WO2016/57834, 2016, A1,
[5] Patent: US2012/108619, 2012, A1,
  • 5
  • [ 911434-04-3 ]
  • [ 944937-53-5 ]
Reference: [1] Patent: WO2013/33899, 2013, A1,
[2] Patent: WO2013/34048, 2013, A1,
  • 6
  • [ 911434-04-3 ]
  • [ 1211540-74-7 ]
Reference: [1] Journal of Medicinal Chemistry, 2012, vol. 55, # 17, p. 7667 - 7685
[2] Journal of Medicinal Chemistry, 2014, vol. 57, # 13, p. 5728 - 5737
  • 7
  • [ 911434-04-3 ]
  • [ 1150617-56-3 ]
Reference: [1] Patent: WO2016/57834, 2016, A1,
Same Skeleton Products
Historical Records